 Home > Active Ingredient News > Antitumor Therapy > Takeda will acquire Maverick Therapeutics to promote T-cell conjugation therapy for solid tumors and expand its new immuno-oncology product portfolio

Takeda will acquire Maverick Therapeutics to promote T-cell conjugation therapy for solid tumors and expand its new immuno-oncology product portfolio

 Last Update: 2021-03-19
 Source: Internet
 Author: User

Tags

half crown

cancer cell proliferation

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Takeda Pharmaceutical Company Limited (businesswire.

businesswire.

Maverick's COBRA platform is designed to safely target a variety of solid tumors, with high specificity and potent activity, while limiting the toxicity of normal tissues.

Prior to this acquisition, businesswire.

businesswire.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.